TNGX tangotx.com: Enterprise Value to EBITDA Ratio

Graphic logo of Tango Therapeutics, Inc. (TNGX)

The dynamics of the base EV/EBITDA multiple demonstrate the market valuation of Tango Therapeutics (TNGX), where 0.00 reflects the latest value of the metric. Strict FDA requirements and patent protection ensure a high barrier to entry in the sector. Tango Therapeutics generates revenue by creating targeted drugs through biopharmaceutical alliances, while simultaneously implementing ESG standards to minimize harmful emissions and adhere to laboratory ethics.

Tango Pharma - TNGX Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/12/2026)

Summary analytical data breakdowns for tangotx.com (TNGX)

- stock price and consensus target price:
Stock Quotes Tango Pharma|TNGX - Average Forecast Price
- company stock capitalization data:
Market Valuation Tango Therapeutics Corp|TNGX - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Tango Therapeutics|TNGX - Book Valuation of Business|Market Value to Book Value Ratio tangotx.com|TNGX - Cumulative Company Assets
- debt and solvency information:
Debt to Equity Tango Therapeutics|TNGX - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Tango Therapeutics, Inc.|TNGX - Company Aggregate Debts|Debt to Book Capitalization Ratio Tango Therapeutics Corp|TNGX - Company Long-Term Indebtedness|Company Short-Term Debt Tango Therapeutics|Quick Liquidity Indicator tangotx.com
- financial results and valuation multiples details:
TNGX - Annual Net Income|Future Profit Tango Therapeutics|TNGX - Market Price to Net Income Ratio|Forward P/E Multiple Tango Therapeutics|TNGX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Tango Therapeutics Corp|TNGX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Tango Therapeutics|TNGX - Earnings per share for the trailing year|Quarterly EPS earnings growth tangotx.com|TNGX - Earnings growth in current year|Net earnings per share growth forecast for next year Tango Therapeutics
Fundamental company analysis:TNGX (Tango Pharma)
Original product of Tango Therapeutics Inc

Tango Therapeutics (TNGX) focuses on attracting leading geneticists to develop innovative cancer therapies, a process that requires significant capital expenditures. The ratio of enterprise value to EBITDA allows for an assessment of the company's real value accounting for its debt load; therefore, the trend of the base EV/EBITDA multiple serves as an indicator of asset overbought conditions and excessive leverage risks.

Competitor analysis for Tango Therapeutics

ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|IOVA - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Immatics Corp|Enterprise Value to EBITDA Ratio Xencor Inc. (XNCR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Compass Therapeutics (CMPX)|Enterprise Value to EBITDA Ratio replimune.com REPL|Lyell Immunopharma, Inc. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Innate Pharma SA IPHA|PYXS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CGEN (Compugen Ltd.) - Enterprise Value to Operating Income Before Depreciation|IO Biotech, Inc. (IOBT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA sutrobio.com (STRO)|Enterprise Value to EBITDA Ratio INKT|HOWL - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio IMMX (Immix Biopharma, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ALXO|EV/EBITDA Multiple CUE (Cue Biopharma)|Business Value to Operating Income Before Depreciation PDSB|Sonnet BioTherapeutics Holdings Inc. - EV/EBITDA Multiple|Company Value to EBITDA MAIA Biotech|Liminatus Pharma Corp (LIMN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics - Business Value to Operating Income Before Depreciation|NXTC (NextCure, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Leap Tx|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intensity Therapeutics (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Synthetic Biologics - Enterprise Value to EBITDA Ratio|Gritstone bio Inc. (GRTS) - Company Value to EBITDA|KA: Enterprise Value to EBITDA Ratio|neximmune.com - Enterprise Value to Operating Income Before Depreciation Ratio|TSBX: EV/EBITDA Multiple|Vaccinex Inc. (VCNX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Tx